Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Voyager Therapeutics, Inc. | vygr-20171231ex3123b26df.htm |
| EX-31.1 - EX-31.1 - Voyager Therapeutics, Inc. | vygr-20171231ex311f85e86.htm |
| EX-23.1 - EX-23.1 - Voyager Therapeutics, Inc. | vygr-20171231ex231e9df05.htm |
| EX-21.1 - EX-21.1 - Voyager Therapeutics, Inc. | vygr-20171231ex211199c06.htm |
| EX-10.22 - EX-10.22 - Voyager Therapeutics, Inc. | vygr-20171231ex10229c9cb.htm |
| EX-10.21 - EX-10.21 - Voyager Therapeutics, Inc. | vygr-20171231ex1021617d8.htm |
| EX-4.1 - EX-4.1 - Voyager Therapeutics, Inc. | vygr-20171231ex4167a89f3.htm |
| 10-K - 10-K - Voyager Therapeutics, Inc. | vygr-20171231x10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Voyager Therapeutics, Inc. (the “Company”) for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his or her knowledge:
|
|
1) |
|
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
2) |
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
|
|
|
|
Date: March 14, 2018 |
|
/s/ Steven M. Paul |
|
|
|
Steven M. Paul |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
Date: March 14, 2018 |
|
/s/ Jane Henderson |
|
|
|
Jane Henderson |
|
|
|
Chief Financial Officer and Senior Vice President of Corporate Development (Principal Financial and Accounting Officer) |